---
title: "Harmony Biosciences Holdings, Inc. (HRMY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HRMY.US.md"
symbol: "HRMY.US"
name: "Harmony Biosciences Holdings, Inc."
industry: "Pharmaceuticals"
datetime: "2026-03-12T16:39:21.084Z"
locales:
  - [en](https://longbridge.com/en/quote/HRMY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HRMY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HRMY.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/HRMY.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/HRMY.US.md)


# Harmony Biosciences Holdings, Inc. (HRMY.US)

## Company Overview

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.harmonybiosciences.com](https://www.harmonybiosciences.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-12T04:30:14.000Z

**Overall: B (0.25)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 188 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21.51% |  |
| Net Profit YoY | 9.07% |  |
| P/B Ratio | 1.91 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1665231277.06 |  |
| Revenue | 868453000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 20.75% | A |
| Profit Margin | 18.27% | A |
| Gross Margin | 77.16% | A |
| Revenue YoY | 21.51% | A |
| Net Profit YoY | 9.07% | C |
| Total Assets YoY | 27.26% | A |
| Net Assets YoY | 32.02% | A |
| Cash Flow Margin | 547.27% | C |
| OCF YoY | 21.51% | A |
| Turnover | 0.76 | B |
| Gearing Ratio | 31.57% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Harmony Biosciences Holdings, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "21.51%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "9.07%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.91",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1665231277.06",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "868453000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "20.75%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "18.27%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "77.16%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "21.51%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "9.07%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "27.26%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "32.02%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "547.27%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "21.51%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.76",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "31.57%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 10.49 | 11/188 | 12.82 | 11.61 | 10.40 |
| PB | 1.91 | 86/188 | 2.75 | 2.57 | 2.34 |
| PS (TTM) | 1.92 | 53/188 | 2.71 | 2.55 | 2.28 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | C | B |
| 03 | Roche (RHHBY.US) | A | B | B | D | C | B |
| 04 | AstraZeneca (AZN.US) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (NVS.US) | A | B | C | D | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-27T05:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 36% |
| Overweight | 2 | 18% |
| Hold | 4 | 36% |
| Underweight | 1 | 9% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 27.83 |
| Highest Target | 62.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/HRMY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/HRMY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/HRMY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/HRMY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**